311 related articles for article (PubMed ID: 34077739)
21. A Novel Molecular Target in
Takano N; Seike M; Sugano T; Matsuda K; Hisakane K; Yoshikawa A; Nakamichi S; Noro R; Gemma A
Anticancer Res; 2022 Feb; 42(2):709-722. PubMed ID: 35093869
[TBL] [Abstract][Full Text] [Related]
22. CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling.
Wang S; Englund E; Kjellman P; Li Z; Ahnlide JK; Rodriguez-Cupello C; Saggioro M; Kanzaki R; Pietras K; Lindgren D; Axelson H; Prinz CN; Swaminathan V; Madsen CD
Nat Cell Biol; 2021 Jul; 23(7):758-770. PubMed ID: 34226698
[TBL] [Abstract][Full Text] [Related]
23. Integrin signalling regulates YAP and TAZ to control skin homeostasis.
Elbediwy A; Vincent-Mistiaen ZI; Spencer-Dene B; Stone RK; Boeing S; Wculek SK; Cordero J; Tan EH; Ridgway R; Brunton VG; Sahai E; Gerhardt H; Behrens A; Malanchi I; Sansom OJ; Thompson BJ
Development; 2016 May; 143(10):1674-87. PubMed ID: 26989177
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells.
Fu J; Liu W; Liu S; Zhao R; Hayashi T; Zhao H; Xiang Y; Mizuno K; Hattori S; Fujisaki H; Ikejima T
Cell Signal; 2024 Jul; 119():111186. PubMed ID: 38643945
[TBL] [Abstract][Full Text] [Related]
25. HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.
Yuan B; Liu J; Shi A; Cao J; Yu Y; Zhu Y; Zhang C; Qiu Y; Luo H; Shi J; Cao X; Xu P; Shen L; Liang T; Zhao B; Feng XH
EMBO J; 2023 Feb; 42(4):e111549. PubMed ID: 36598329
[TBL] [Abstract][Full Text] [Related]
26. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
[TBL] [Abstract][Full Text] [Related]
27. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of yes-associated protein/YAP and transcriptional coactivator with PDZ-binding motif/TAZ activates intestinal fibroblasts to promote intestinal obstruction in Crohn's disease.
Ou W; Xu W; Liu F; Guo Y; Huang Z; Feng T; Liu CY; Du P
EBioMedicine; 2021 Jul; 69():103452. PubMed ID: 34186485
[TBL] [Abstract][Full Text] [Related]
29. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
Horie M; Saito A; Ohshima M; Suzuki HI; Nagase T
Cancer Sci; 2016 Dec; 107(12):1755-1766. PubMed ID: 27627196
[TBL] [Abstract][Full Text] [Related]
30. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
[TBL] [Abstract][Full Text] [Related]
31. YAP promotes erlotinib resistance in human non-small cell lung cancer cells.
Hsu PC; You B; Yang YL; Zhang WQ; Wang YC; Xu Z; Dai Y; Liu S; Yang CT; Li H; Hu B; Jablons DM; You L
Oncotarget; 2016 Aug; 7(32):51922-51933. PubMed ID: 27409162
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.
Pfeifer M; Brammeld JS; Price S; Pilling J; Bhavsar D; Farcas A; Bateson J; Sundarrajan A; Miragaia RJ; Guan N; Arnold S; Tariq L; Grondine M; Talbot S; Guerriero ML; O'Neill DJ; Young J; Company C; Dunn S; Thorpe H; Martin MJ; Maratea K; Barrell D; Ahdesmaki M; Mettetal JT; ; Brownell J; McDermott U
Commun Biol; 2024 Apr; 7(1):497. PubMed ID: 38658677
[TBL] [Abstract][Full Text] [Related]
33. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
[TBL] [Abstract][Full Text] [Related]
34. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
[TBL] [Abstract][Full Text] [Related]
35. Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth.
Koo JH; Plouffe SW; Meng Z; Lee DH; Yang D; Lim DS; Wang CY; Guan KL
Genes Dev; 2020 Jan; 34(1-2):72-86. PubMed ID: 31831627
[TBL] [Abstract][Full Text] [Related]
36. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A
Ann Oncol; 2017 Oct; 28(10):2451-2457. PubMed ID: 28961841
[TBL] [Abstract][Full Text] [Related]
37. Targeting
Liu S; Li S; Hai J; Wang X; Chen T; Quinn MM; Gao P; Zhang Y; Ji H; Cross DAE; Wong KK
Clin Cancer Res; 2018 Jun; 24(11):2594-2604. PubMed ID: 29298799
[No Abstract] [Full Text] [Related]
38. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC.
Choi W; Kim J; Park J; Lee DH; Hwang D; Kim JH; Ashktorab H; Smoot D; Kim SY; Choi C; Koh GY; Lim DS
Cancer Res; 2018 Jun; 78(12):3306-3320. PubMed ID: 29669762
[TBL] [Abstract][Full Text] [Related]
39. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
40. MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.
Lo Sardo F; Forcato M; Sacconi A; Capaci V; Zanconato F; Di Agostino S; Del Sal G; Pandolfi PP; Strano S; Bicciato S; Blandino G
Carcinogenesis; 2017 Jan; 38(1):64-75. PubMed ID: 27797825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
